Talus Bio aims to revolutionize drug development for gene regulators by enabling the ability to study gene regulatory proteins (GRPs) in a living cell environment. The company’s initial focus is on small-molecule drug development in oncology.
Founded in 2020 as a spin out of the University of Washington and Altius Institute for Biomedical Sciences, the company’s platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. After treating the cell with a potential drug, Talus uses its platform to remove everything in the cell that isn’t stuck to the DNA. That leaves behind a collection of potential drug targets for analysis. Using mass spectrometry combined with data analytics and machine learning the potential targets can be identified.
A single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment.
The company is developing internal programs against previously undruggable gene regulators in cancers as well as partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs. Talus’s approach has many potential uses beyond oncology as well, including aging.
Subscribe for alerts on new companies featured on Startups.Bio
U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women around the world face the emotional and financial toll of age-related infertility. As …
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for …
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond …
